Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based compensation (Tables)

Stock-based compensation (Tables)

3 Months Ended

Mar. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Total Stock-Based Compensation Expense Related to Share-Based Awards under the Pieris Plan

Total stock-based compensation expense, related to all share-based awards under the Pieris Plan to executive officers, directors, employees and consultants recognized for the three months ended March 31, 2015, was comprised of the following:


	Three months ended March 31, 2015
Research and Development	$	51,038
General and administrative		166,297

Total stock-option expense	$	217,335

Schedule of Weighted-Average Assumptions Used for Calculating Value of Options Granted

The fair value of option grants was estimated using the Black-Scholes model. The following table describes the weighted-average assumptions used for calculating the value of options granted for the three months ended March 31, 2015:


	Three months ended March 31, 2015
Dividend yield		0.0	%
Expected volatility		75.1	%
Weighted average risk-free interest rate		1.66	%
Expected term		5.8 years

Schedule of Information Regarding Stock Option Activity

A summary of the Company´s stock option activity and related information is as follows:


	Number of shares		Weighted-Average Exercise Price		Weighted-Average Contractual Life
Outstanding at December 31, 2014		2,519,500	$	2.00		5.6-5.8 years
Options granted		25,000	$	2.85		5.8 years
Options exercised		—		—		—
Options canceled or expired		—		—		—
Outstanding at March 31, 2015		2,544,500	$	2.01		5.6-5.8 years
Vested or expected to vest at March 31, 2015		598,396	$	2.00		—
Exercisable at March 31, 2015		598,396	$	2.00		—